Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells

Aurora Kinase Inhibitor PHA-739358 Suppresses Growth of Hepatocellular Carcinoma In Vitro and in a Xenograft Mouse Model

(2015) Daniel Benten et al.   NEOPLASIA

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia

(2013) Hagop M. Kantarjian et al.   CANCER

Aurora B inhibitor barasertib and cytarabine exert a greater-than-additive cytotoxicity in acute myeloid leukemia cells

(2013) Takahiro Yamauchi et al.   CANCER SCIENCE

Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cellsviaAKT signaling

(2013) Jing Yang et al.   INTERNATIONAL JOURNAL OF CANCER

A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors

(2013) E. Raymond et al.   INVESTIGATIONAL NEW DRUGS

A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies

(2013) Carlos Graux et al.   LEUKEMIA RESEARCH

A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors

(2013) M. Mita et al.   Targeted Oncology

Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro

(2012) Mohsin Shah et al.   BLOOD CELLS MOLECULES AND DISEASES

Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL

(2012) Qiang Wen et al.   CELL

Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism

(2012) Kevin R. Kelly et al.   INTERNATIONAL JOURNAL OF CANCER

Aurora kinase inhibitors: Progress towards the clinic

(2012) Madhu Kollareddy et al.   INVESTIGATIONAL NEW DRUGS

Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models

(2012) Clarisse Thiollier et al.   JOURNAL OF EXPERIMENTAL MEDICINE

MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia

(2012) F J Giles et al.   LEUKEMIA

Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target

(2012) S A Hartsink-Segers et al.   LEUKEMIA

Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells

(2012) Aarthi Jayanthan et al.   LEUKEMIA & LYMPHOMA

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia

(2011) B. Lowenberg et al.   BLOOD

Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients

(2011) Ruriko Tanaka et al.   CANCER LETTERS

Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model

(2011) Hongfeng Yuan et al.   CARCINOGENESIS

Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays

(2011) M. G. Manfredi et al.   CLINICAL CANCER RESEARCH

AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas

(2011) Wenqing Qi et al.   INTERNATIONAL JOURNAL OF CANCER

A Phase I study to assess the safety, pharmacokinetics and efficacy of barasertib (AZD1152), an Aurora B kinase inhibitor, in Japanese patients with advanced acute myeloid leukemia

(2011) Kosuke Tsuboi et al.   LEUKEMIA RESEARCH

Drug-Resistant Aurora A Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors MLN8054 and MLN8237

(2010) Dominic A. Sloane et al.   ACS Chemical Biology

Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

(2010) Tianjun Zhou et al.   Chemical Biology & Drug Design

The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib

(2010) Kevin R. Kelly et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics?

(2010) A. A. Dar et al.   MOLECULAR CANCER THERAPEUTICS

Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: What Is the “Best” Therapy?

(2010) Meetu Agrawal et al.   Current Oncology Reports

Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2

(2009) Giorgio Cozza et al.   BIOCHEMICAL JOURNAL

Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia

(2009) Nicholas J. Donato et al.   BIOCHEMICAL PHARMACOLOGY

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

(2009) S. Branford et al.   BLOOD

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

(2009) H. Kantarjian et al.   BLOOD

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily

(2009) Hagop Kantarjian et al.   CANCER

AZD1152 Rapidly and Negatively Affects the Growth and Survival of Human Acute Myeloid Leukemia Cells In vitro and In vivo

(2009) A. Oke et al.   CANCER RESEARCH

A Phase I Dose-Escalation Study of Danusertib (PHA-739358) Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors

(2009) R. B. Cohen et al.   CLINICAL CANCER RESEARCH

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

(2009) F. Palandri et al.   HAEMATOLOGICA

Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen

(2009) John McLaughlin et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Predictors of Primary Imatinib Resistance in Chronic Myelogenous Leukemia Are Distinct From Those in Secondary Imatinib Resistance

(2009) Wenyong W. Zhang et al.   JOURNAL OF CLINICAL ONCOLOGY

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I

(2008) A. Gontarewicz et al.   BLOOD

Aurora Kinase A Inhibition Leads to p73-Dependent Apoptosis in p53-Deficient Cancer Cells

(2008) Altaf A. Dar et al.   CANCER RESEARCH

Molecular Basis of Drug Resistance in Aurora Kinases

(2008) Fiona Girdler et al.   CHEMISTRY & BIOLOGY

Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts

(2008) E. Walsby et al.   HAEMATOLOGICA

Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up

(2008) F. Palandri et al.   HAEMATOLOGICA

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

(2008) Hugues de Lavallade et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants

(2008) Sara Redaelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity†

(2008) Steven Howard et al.   JOURNAL OF MEDICINAL CHEMISTRY

A structural insight into CK2 inhibition

(2008) Marco Mazzorana et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY